244 related articles for article (PubMed ID: 11194468)
1. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Fleeman LM; Irwin PJ; Phillips PA; West J
Aust Vet J; 2000 Dec; 78(12):825-30. PubMed ID: 11194468
[TBL] [Abstract][Full Text] [Related]
2. Syndrome of inappropriate antidiuresis without involving inappropriate secretion of vasopressin in an elderly woman: effect of intravenous administration of the nonpeptide vasopressin V2 receptor antagonist OPC-31260.
Kamoi K
Nephron; 1997; 76(1):111-5. PubMed ID: 9171309
[TBL] [Abstract][Full Text] [Related]
3. Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Yamamoto H; Kimura K; Horikirizono H; Tamura Y; Kambayashi S; Baba K; Okuda M; Mizuno T; Igase M
J Vet Med Sci; 2023 Oct; 85(10):1047-1051. PubMed ID: 37587049
[TBL] [Abstract][Full Text] [Related]
4. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Saito T; Ishikawa S; Abe K; Kamoi K; Yamada K; Shimizu K; Saruta T; Yoshida S
J Clin Endocrinol Metab; 1997 Apr; 82(4):1054-7. PubMed ID: 9100572
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats.
Fujisawa G; Ishikawa S; Tsuboi Y; Okada K; Saito T
Kidney Int; 1993 Jul; 44(1):19-23. PubMed ID: 8355461
[TBL] [Abstract][Full Text] [Related]
6. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
Naitoh M; Suzuki H; Murakami M; Matsumoto A; Arakawa K; Ichihara A; Nakamoto H; Oka K; Yamamura Y; Saruta T
Am J Physiol; 1994 Dec; 267(6 Pt 2):H2245-54. PubMed ID: 7810724
[TBL] [Abstract][Full Text] [Related]
8. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
[TBL] [Abstract][Full Text] [Related]
9. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans.
Shimizu K
Kidney Int; 1995 Jul; 48(1):220-6. PubMed ID: 7564082
[TBL] [Abstract][Full Text] [Related]
10. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
11. Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Mini-Breed Puppy Associated With Aspiration Pneumonia.
Martínez R; Torrente C
Top Companion Anim Med; 2017 Dec; 32(4):146-150. PubMed ID: 29525234
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T
Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020
[TBL] [Abstract][Full Text] [Related]
13. Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs.
Nakamura S; Hirano T; Onogawa T; Itoh S; Hashimoto A; Yamamura Y; Kondo K; Mori T; Kambe T
J Pharmacol Sci; 2004 Apr; 94(4):426-33. PubMed ID: 15107583
[TBL] [Abstract][Full Text] [Related]
14. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
Kazama I; Arata T; Michimata M; Hatano R; Suzuki M; Miyama N; Sanada S; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Nephrol Dial Transplant; 2007 Jan; 22(1):68-76. PubMed ID: 16702208
[TBL] [Abstract][Full Text] [Related]
15. Syndrome of inappropriate antidiuretic hormone secretion in a dog with a histiocytic sarcoma.
Barrot AC; Bédard A; Dunn M
Can Vet J; 2017 Jul; 58(7):713-715. PubMed ID: 28698689
[TBL] [Abstract][Full Text] [Related]
16. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Murphy T; Dhar R; Diringer M
Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
[TBL] [Abstract][Full Text] [Related]
17. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
[TBL] [Abstract][Full Text] [Related]
18. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
Burrell LM; Phillips PA; Risvanis J; Chan RK; Aldred KL; Johnston CI
Am J Physiol; 1998 Jul; 275(1):H176-82. PubMed ID: 9688911
[TBL] [Abstract][Full Text] [Related]
20. Effects of anesthesia, surgery, and intravenous administration of fluids on plasma antidiuretic hormone concentrations in healthy dogs.
Hauptman JG; Richter MA; Wood SL; Nachreiner RF
Am J Vet Res; 2000 Oct; 61(10):1273-6. PubMed ID: 11039560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
